Caseware UK (AP4) 2024.0.164 2024.0.164 2025-05-312025-05-31truefalse192024-06-01falseNo description of principal activity19false 04712793 2024-06-01 2025-05-31 04712793 2023-06-01 2024-05-31 04712793 2025-05-31 04712793 2024-05-31 04712793 2023-06-01 04712793 1 2024-06-01 2025-05-31 04712793 1 2023-06-01 2024-05-31 04712793 2 2024-06-01 2025-05-31 04712793 2 2023-06-01 2024-05-31 04712793 5 2024-06-01 2025-05-31 04712793 d:Director1 2024-06-01 2025-05-31 04712793 e:Buildings 2024-06-01 2025-05-31 04712793 e:Buildings 2025-05-31 04712793 e:Buildings 2024-05-31 04712793 e:Buildings e:OwnedOrFreeholdAssets 2024-06-01 2025-05-31 04712793 e:Buildings e:LeasedAssetsHeldAsLessee 2024-06-01 2025-05-31 04712793 e:PlantMachinery 2024-06-01 2025-05-31 04712793 e:PlantMachinery 2025-05-31 04712793 e:PlantMachinery 2024-05-31 04712793 e:PlantMachinery e:OwnedOrFreeholdAssets 2024-06-01 2025-05-31 04712793 e:PlantMachinery e:LeasedAssetsHeldAsLessee 2024-06-01 2025-05-31 04712793 e:MotorVehicles 2024-06-01 2025-05-31 04712793 e:MotorVehicles 2025-05-31 04712793 e:MotorVehicles 2024-05-31 04712793 e:MotorVehicles e:OwnedOrFreeholdAssets 2024-06-01 2025-05-31 04712793 e:MotorVehicles e:LeasedAssetsHeldAsLessee 2024-06-01 2025-05-31 04712793 e:OfficeEquipment 2024-06-01 2025-05-31 04712793 e:OfficeEquipment 2025-05-31 04712793 e:OfficeEquipment 2024-05-31 04712793 e:OfficeEquipment e:OwnedOrFreeholdAssets 2024-06-01 2025-05-31 04712793 e:OfficeEquipment e:LeasedAssetsHeldAsLessee 2024-06-01 2025-05-31 04712793 e:OwnedOrFreeholdAssets 2024-06-01 2025-05-31 04712793 e:LeasedAssetsHeldAsLessee 2024-06-01 2025-05-31 04712793 e:CurrentFinancialInstruments 2025-05-31 04712793 e:CurrentFinancialInstruments 2024-05-31 04712793 e:Non-currentFinancialInstruments 2025-05-31 04712793 e:Non-currentFinancialInstruments 2024-05-31 04712793 e:CurrentFinancialInstruments e:WithinOneYear 2025-05-31 04712793 e:CurrentFinancialInstruments e:WithinOneYear 2024-05-31 04712793 e:Non-currentFinancialInstruments e:AfterOneYear 2025-05-31 04712793 e:Non-currentFinancialInstruments e:AfterOneYear 2024-05-31 04712793 e:Non-currentFinancialInstruments e:BetweenOneTwoYears 2025-05-31 04712793 e:Non-currentFinancialInstruments e:BetweenOneTwoYears 2024-05-31 04712793 e:Non-currentFinancialInstruments e:BetweenTwoFiveYears 2025-05-31 04712793 e:Non-currentFinancialInstruments e:BetweenTwoFiveYears 2024-05-31 04712793 e:Non-currentFinancialInstruments e:MoreThanFiveYears 2025-05-31 04712793 e:Non-currentFinancialInstruments e:MoreThanFiveYears 2024-05-31 04712793 e:ShareCapital 2024-06-01 2025-05-31 04712793 e:ShareCapital 2025-05-31 04712793 e:ShareCapital 2023-06-01 2024-05-31 04712793 e:ShareCapital 2024-05-31 04712793 e:ShareCapital 2023-06-01 04712793 e:SharePremium 2024-06-01 2025-05-31 04712793 e:SharePremium 2025-05-31 04712793 e:SharePremium 1 2024-06-01 2025-05-31 04712793 e:SharePremium 2 2024-06-01 2025-05-31 04712793 e:SharePremium 2023-06-01 2024-05-31 04712793 e:SharePremium 2024-05-31 04712793 e:SharePremium 2023-06-01 04712793 e:SharePremium 1 2023-06-01 2024-05-31 04712793 e:SharePremium 2 2023-06-01 2024-05-31 04712793 e:CapitalRedemptionReserve 2024-06-01 2025-05-31 04712793 e:CapitalRedemptionReserve 2025-05-31 04712793 e:CapitalRedemptionReserve 1 2024-06-01 2025-05-31 04712793 e:CapitalRedemptionReserve 2 2024-06-01 2025-05-31 04712793 e:CapitalRedemptionReserve 2023-06-01 2024-05-31 04712793 e:CapitalRedemptionReserve 2024-05-31 04712793 e:CapitalRedemptionReserve 2023-06-01 04712793 e:CapitalRedemptionReserve 2 2023-06-01 2024-05-31 04712793 e:RevaluationReserve 2024-06-01 2025-05-31 04712793 e:RevaluationReserve 2025-05-31 04712793 e:RevaluationReserve 1 2024-06-01 2025-05-31 04712793 e:RevaluationReserve 2 2024-06-01 2025-05-31 04712793 e:RevaluationReserve 5 2024-06-01 2025-05-31 04712793 e:RevaluationReserve 2023-06-01 2024-05-31 04712793 e:RevaluationReserve 2024-05-31 04712793 e:RevaluationReserve 2023-06-01 04712793 e:RevaluationReserve 1 2023-06-01 2024-05-31 04712793 e:RevaluationReserve 2 2023-06-01 2024-05-31 04712793 e:RevaluationReserve 8 2023-06-01 2024-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2024-06-01 2025-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2025-05-31 04712793 e:RetainedEarningsAccumulatedLosses 1 2024-06-01 2025-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2 2024-06-01 2025-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2023-06-01 2024-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2024-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2023-06-01 04712793 e:RetainedEarningsAccumulatedLosses 1 2023-06-01 2024-05-31 04712793 e:RetainedEarningsAccumulatedLosses 2 2023-06-01 2024-05-31 04712793 e:AcceleratedTaxDepreciationDeferredTax 2025-05-31 04712793 e:AcceleratedTaxDepreciationDeferredTax 2024-05-31 04712793 e:TaxLossesCarry-forwardsDeferredTax 2025-05-31 04712793 e:TaxLossesCarry-forwardsDeferredTax 2024-05-31 04712793 e:OtherDeferredTax 2025-05-31 04712793 e:OtherDeferredTax 2024-05-31 04712793 d:OrdinaryShareClass1 2024-06-01 2025-05-31 04712793 d:OrdinaryShareClass1 2025-05-31 04712793 d:OrdinaryShareClass2 2024-06-01 2025-05-31 04712793 d:OrdinaryShareClass2 2025-05-31 04712793 d:OrdinaryShareClass3 2024-06-01 2025-05-31 04712793 d:OrdinaryShareClass4 2024-06-01 2025-05-31 04712793 d:OrdinaryShareClass4 2025-05-31 04712793 d:FRS102 2024-06-01 2025-05-31 04712793 d:Audited 2024-06-01 2025-05-31 04712793 d:FullAccounts 2024-06-01 2025-05-31 04712793 d:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 04712793 e:Subsidiary1 2024-06-01 2025-05-31 04712793 e:Subsidiary1 1 2024-06-01 2025-05-31 04712793 e:WithinOneYear 2025-05-31 04712793 e:WithinOneYear 2024-05-31 04712793 e:BetweenOneFiveYears 2025-05-31 04712793 e:BetweenOneFiveYears 2024-05-31 04712793 e:HirePurchaseContracts e:WithinOneYear 2025-05-31 04712793 e:HirePurchaseContracts e:WithinOneYear 2024-05-31 04712793 e:HirePurchaseContracts e:BetweenOneFiveYears 2025-05-31 04712793 e:HirePurchaseContracts e:BetweenOneFiveYears 2024-05-31 04712793 d:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 04712793 2 2024-06-01 2025-05-31 04712793 5 2024-06-01 2025-05-31 04712793 6 2024-06-01 2025-05-31 04712793 e:ShareCapital 1 2024-06-01 2025-05-31 04712793 e:ShareCapital 2 2024-06-01 2025-05-31 04712793 e:ShareCapital 1 2023-06-01 2024-05-31 04712793 e:ShareCapital 2 2023-06-01 2024-05-31 04712793 e:Buildings e:LeasedAssetsHeldAsLessee 2025-05-31 04712793 e:Buildings e:LeasedAssetsHeldAsLessee 2024-05-31 04712793 e:LeasedAssetsHeldAsLessee 2025-05-31 04712793 e:LeasedAssetsHeldAsLessee 2024-05-31 04712793 f:PoundSterling 2024-06-01 2025-05-31 04712793 e:RetainedEarningsAccumulatedLosses 5 2024-06-01 2025-05-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 04712793









THAMES CRYOGENICS LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MAY 2025

 
THAMES CRYOGENICS LIMITED
REGISTERED NUMBER: 04712793

STATEMENT OF FINANCIAL POSITION
AS AT 31 MAY 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,048,701
831,728

Investments
 5 
1
1

  
1,048,702
831,729

Current assets
  

Stocks
 6 
614,530
344,392

Debtors: amounts falling due within one year
 7 
1,206,779
782,692

Cash at bank and in hand
 8 
984,699
966,812

  
2,806,008
2,093,896

Creditors: amounts falling due within one year
 9 
(2,252,933)
(1,246,906)

Net current assets
  
 
 
553,075
 
 
846,990

Total assets less current liabilities
  
1,601,777
1,678,719

Creditors: amounts falling due after more than one year
 10 
(9,501)
(205,471)

Provisions for liabilities
  

Deferred tax
 13 
(118,034)
(52,974)

  
 
 
(118,034)
 
 
(52,974)

Net assets
  
1,474,242
1,420,274


Capital and reserves
  

Called up share capital 
 14 
158,344
311,034

Share premium account
 15 
213,966
213,966

Revaluation reserve
 15 
398,088
278,217

Capital redemption reserve
 15 
257,690
105,000

Profit and loss account
 15 
446,154
512,057

  
1,474,242
1,420,274


Page 1

 
THAMES CRYOGENICS LIMITED
REGISTERED NUMBER: 04712793
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MAY 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the Statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 17 April 2026.




M Evans
Director

The notes on pages 5 to 19 form part of these financial statements.

Page 2
 

 
THAMES CRYOGENICS LIMITED


 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2025



Called up share capital
Share premium account
Capital redemption reserve
Revaluation reserve
Profit and loss account
Total equity


£
£
£
£
£
£


At 1 June 2024
311,034
213,966
105,000
278,217
512,057
1,420,274



Comprehensive income for the year


Profit for the year
-
-
-
-
196,655
196,655


Surplus on revaluation of freehold property
-
-
-
155,242
-
155,242


Deferred tax on revaluation of tangible fixed assets
-
-
-
(37,241)
-
(37,241)

Total comprehensive income for the year
-
-
-
118,001
196,655
314,656



Contributions by and distributions to owners


Dividends: Equity capital
-
-
-
-
(260,688)
(260,688)


Cancellation of deferred shares
-
-
152,690
-
-
152,690


Cancellation of deferred shares
(152,690)
-
-
-
-
(152,690)


Difference between historical cost depreciation and revaluation depreciation
-
-
-
1,870
(1,870)
-



At 31 May 2025
158,344
213,966
257,690
398,088
446,154
1,474,242



The notes on pages 5 to 19 form part of these financial statements.

Page 3

 

 
THAMES CRYOGENICS LIMITED


 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2024



Called up share capital
Share premium account
Capital redemption reserve
Revaluation reserve
Profit and loss account
Total equity


£
£
£
£
£
£


At 1 June 2023
311,034
213,966
105,000
277,662
180,708
1,088,370



Comprehensive income for the year


Profit for the year
-
-
-
-
330,429
330,429


Deferred tax on revaluation of tangible fixed assets
-
-
-
1,475
-
1,475

Total comprehensive income for the year
-
-
-
1,475
330,429
331,904


Difference between historical cost depreciation and revalued depreciation
-
-
-
(920)
920
-



At 31 May 2024
311,034
213,966
105,000
278,217
512,057
1,420,274



The notes on pages 5 to 19 form part of these financial statements.

Page 4
 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

1.


General information

Thames Cryogenics Limited is a company limited by shares, incorporated in England and Wales. The address of the registered office is Gooch Drive, Southmead Industrial Estate, Didcot, Oxfordshire, OX11 7PR.

The company is engaged in the manufacture, supply, installation, and servicing of cryogenic storage and distribution equipment.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The company is the parent undertaking of a small group and has therefore taken advantage of the exemption available under section 399 of the Companies Act 2006 from the requirement to prepare group financial statements. Accordingly, these financial statements present information about the company as an individual undertaking only and do not include the results or financial position of its group.

The following principal accounting policies have been applied:

  
2.2

Going concern

The directors note that the company is trading adequately and if this continues they will have sufficient working capital and other finance available to continue trading for a period of not less than twelve months from the date of approving these financial statements. As such, the directors believe that there are no significant uncertainties in their assessment of whether the business is going concern and therefore have prepared the accounts on a going concern basis.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Page 5

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

2.Accounting policies (continued)


2.3
Foreign currency translation (continued)

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

  
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to the Statement of comprehensive income on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.6

Interest income

Interest income is recognised in the Statement of comprehensive income using the effective interest method.

Page 6

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

2.Accounting policies (continued)

 
2.7

Finance costs

Finance costs are charged to the Statement of comprehensive income over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.8

Borrowing costs

All borrowing costs are recognised in the Statement of comprehensive income in the year in which they are incurred.

 
2.9

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.10

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


Page 7

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

2.Accounting policies (continued)

 
2.11

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Freehold property
-
Land not depreciated, building 2% straight line
Plant and machinery
-
20% straight line
Motor vehicles
-
25% straight line
Office equipment
-
20% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income.

 
2.12

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the reporting date.

Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in the Statement of comprehensive income.

 
2.13

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.14

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

Page 8

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

2.Accounting policies (continued)

 
2.15

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.16

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.17

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

  
2.18

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found,an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the Statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Page 9

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

2.Accounting policies (continued)

 
2.19

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to the Statement of comprehensive income.

 
2.20

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 19 (2024 - 19).

Page 10

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

4.


Tangible fixed assets


Freehold property
Plant and machinery
Motor vehicles
Office equipment
Total

£
£
£
£
£



Cost or valuation


At 1 June 2024
730,000
131,454
163,512
145,480
1,170,446


Additions
-
15,305
76,009
11,667
102,981


Revaluations
140,000
-
-
-
140,000



At 31 May 2025

870,000
146,759
239,521
157,147
1,413,427



Depreciation


At 1 June 2024
11,309
130,556
82,422
114,431
338,718


Charge for the year on owned assets
6,277
1,153
14,220
552
22,202


Charge for the year on financed assets
-
-
19,048
-
19,048


On revalued assets
(15,242)
-
-
-
(15,242)



At 31 May 2025

2,344
131,709
115,690
114,983
364,726



Net book value



At 31 May 2025
867,656
15,050
123,831
42,164
1,048,701



At 31 May 2024
718,691
898
81,090
31,049
831,728

Page 11

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

           4.Tangible fixed assets (continued)

The net book value of assets held under finance leases or hire purchase contracts, included above, are as follows:


2025
2024
£
£



Motor vehicles
26,985
46,033

26,985
46,033

Cost or valuation at 31 May 2025 is as follows:

Land and buildings
£


At cost
540,301
Valuation surplus:

Revaluation of £170,000 on 27 July 2018, £19,699 on 30 June 2022 and £140,000 on 6 February 2025
329,699



870,000

The freehold property was valued at fair value by an external valuer, Marriotts on 6 February 2025.

If the land and buildings had not been included at valuation they would have been included under the historical cost convention as follows:

2025
2024
£
£



Cost
540,301
540,301

Accumulated depreciation
(152,572)
(144,425)

Net book value
387,729
395,876

Page 12

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost and net book value


At 1 June 2024
1



At 31 May 2025
1





Subsidiary undertaking


The following was a subsidiary undertaking of the Company:

Name

Registered office

Principal activity

Class of shares

Holding

IS4 Cryogenics Ltd
Gooch Drive, Southmead Industrial park, Didcot, Oxfordshire, United Kingdom, OX11 7PR
Servicing, maintenance and installation of cryogenic control systems, gas monitoring and equipment.
Ordinary
 80%


6.


Stocks

2025
2024
£
£

Raw materials
104,928
78,461

Work in progress
509,602
265,931

614,530
344,392


Page 13

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

7.


Debtors

2025
2024
£
£


Trade debtors
1,001,286
468,660

Amounts owed by group undertakings
18,909
95,794

Other debtors
40,998
79,253

Prepayments and accrued income
145,586
138,985

1,206,779
782,692


The amounts owed by group undertakings includes a loan with interest. There are no contractual terms in respect of repayment and therefore the balance is shown as due within one year.


8.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
984,699
966,812

Less: bank overdrafts
(13,247)
-

971,452
966,812



9.


Creditors: Amounts falling due within one year

2025
2024
£
£

Bank overdrafts
13,247
-

Bank loans
16,722
10,648

Mortgage
-
28,610

Trade creditors
383,683
198,193

Corporation tax
62,547
106,718

Other taxation and social security
98,990
63,433

Obligations under finance lease and hire purchase contracts
7,267
15,635

Other creditors
493,336
88,180

Accruals and deferred income
1,177,141
735,489

2,252,933
1,246,906


Hire purchase contracts are secured against the assets to which they relate.

The bank loan and mortgage is secured against a company debenture for the total loan amount.

Page 14

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

10.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Bank loans
-
16,934

Mortgage
-
169,880

Net obligations under finance leases and hire purchase contracts
9,501
18,657

9,501
205,471


Hire purchase contracts are secured against the assets to which they relate.

The bank loan and mortgage is secured against a company debenture for the total loan amount.

Page 15

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

11.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Bank loans
16,722
10,648

Mortgage
-
28,610


16,722
39,258

Amounts falling due 1-2 years

Bank loans
-
16,934

Mortgage
-
28,610


-
45,544

Amounts falling due 2-5 years

Mortgage
-
85,829


-
85,829

Amounts falling due after more than 5 years

Mortgage
-
55,441

-
55,441

16,722
226,072



12.


Hire purchase and finance leases


Minimum lease payments under hire purchase fall due as follows:

2025
2024
£
£


Within one year
7,267
15,635

Between 1-5 years
9,501
18,657

16,768
34,292

Page 16

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

13.


Deferred taxation




2025


£






At beginning of year
52,974


Charged to the profit and loss account
27,819


Charged to other comprehensive income
37,241



At end of year
118,034

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
36,195
18,376

Short term timing difference
-
(10,000)

Capital gain on revalued property
81,839
44,598

118,034
52,974


14.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



60,827 Ordinary B shares of £1.00 each
60,827
60,827
38,620 Ordinary C shares of £0.10 each
3,862
3,862
 Nil (2024 – 152,690) shares of £1.00 each
-
152,690
93,655 Ordinary shares of £1.00 each
93,655
93,655

158,344

311,034

The Ordinary, Ordinary B and Ordinary C class shares have voting and capital distribution rights. The shares are a separate class of share for the payment of dividends.

The deferred class shares have no voting and capital distribution rights.

On 20 May 2025, the company cancelled and extinguished 152,690 issued Deferred shares of £1.00 each, all of which were fully paid. The amount by which the share capital was reduced, £152,690, was credited to Capital redemption reserve.


Page 17

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

15.


Reserves

Share premium account

The share premium accounts represent the value of share issued at more than par value.

Revaluation reserve

The revaluation reserve represents the cumulative unrealised gain on revaluation of tangible fixed assets less deferred tax.

Capital redemption reserve

The capital redemption reserve represents share capital repurchased and cancelled by the company.

Profit and loss account

Profit and loss account includes all current and prior period retained profits and losses.


16.


Pension commitments

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £7,184 (2024 - £7,041). Contributions totalling £4,179 (2024 - £3,422) were payable at the year end and are included in creditors.


17.


Commitments under operating leases

At 31 May 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
38,295
38,146

Later than 1 year and not later than 5 years
91,759
67,223

130,054
105,369


18.


Related party transactions

During the year, the company was recharged £72,378 (2024 - £70,904) of costs from it's subsidiary. At the year end, the company was due £18,909 (2024 - £95,794) from its subsidiary.

Included within other creditors is an amount of £91,753 
(2024 - £Nil) owed to the directors in respect of dividends declared but not yet paid.

Included within other creditors is an amount of £168,935 
(2024: £Nil) payable to shareholders in respect of dividends declared but not yet paid.

Page 18

 
THAMES CRYOGENICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025

19.


Controlling party

There is no controlling party.


20.


Auditors' information

The auditors' report on the financial statements for the year ended 31 May 2025 was unqualified.

The audit report was signed on 17 April 2026 by Nigel Goodman (Senior statutory auditor) on behalf of Barnes Roffe Audit Limited.

 
Page 19